LENZ
LENZ Therapeutics, Inc.
Next earnings Jul 28, 2026 · consensus $-1.09 EPS, $2.54M rev
Last earnings -0.7% on 2026-05-11
$5.82
▲ +5.63%$5.82▼ -80.91%
over 1Y
L $5.51EODHDH $49.05
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.6%
1W+0.0%
1M-24.7%
3M-30.7%
YTD-63.6%
1Y-80.9%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.08x); but unprofitable (net margin -430.3%).
Revenue (FY2025) $19.1M · FY2025
LENZ Therapeutics, Inc. shows $19.1M in FY2025 revenue, a -430.3% net margin, and -28.9% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $19.1M |
| Gross profit | — | — | — | — | — |
| Operating income | -$60.4M | -$106M | -$72.4M | -$58.6M | -$91.1M |
| Net income | -$70.8M | -$101M | -$70.0M | -$49.8M | -$82.1M |
| Diluted EPS | -$2.45 | -$1.84 | -$35.71 | -$2.34 | -$2.85 |
| Net margin | — | — | — | — | -430.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$157M
EV / EBITDA—
EV / Sales8.2
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-45.0%
FCF yield-38.4%
Quality & risk
ROIC (est.)-25.3%
Free cash flow-$70.0M
Total debt—
Net cash$25.2M
Altman Z-Score4.22 safe
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+13.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗SCHEDULE 13GFiling2026-06-26open ↗4Period ending 2026-06-152026-06-15open ↗4Period ending 2026-06-152026-06-15open ↗4Period ending 2026-06-152026-06-15open ↗4Period ending 2026-06-152026-06-15open ↗4Period ending 2026-06-152026-06-15open ↗4Period ending 2026-06-152026-06-15open ↗4Period ending 2026-06-152026-06-15open ↗8-KPeriod ending 2026-06-122026-06-12open ↗10-QPeriod ending 2026-03-312026-05-11open ↗8-KPeriod ending 2026-05-112026-05-11open ↗ARSPeriod ending 2025-12-312026-04-28open ↗
Frequently asked
- Is LENZ Therapeutics, Inc. (LENZ) a buy?
- LENZ currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.08x); but unprofitable (net margin -430.3%).
- What is LENZ Therapeutics, Inc.'s quality score?
- LENZ scores 35.23529411764706/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001815776, latest 10-Q filed 2026-05-11) · EODHD · as of 6/26/2026, 6:17:35 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.